Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Depreciation & Amortization (CF) of $386000.0 for Q1 2026, up 1.85% year-over-year from $379000.0 in Q1 2025, and down 1.53% quarter-over-quarter from $392000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $386000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $386000.0, up 1.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 15.76% YoY), and the FY2025 annual result was $1.5 million, up 37.41% from the prior year.
- Depreciation & Amortization (CF) declined to $386000.0 in Q1 2026 per MDGL's latest filing, from $392000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $392000.0 in Q4 2025 and troughed at $107000.0 in Q1 2022.
- A 5-year average of $234235.3 and a median of $168000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) retreated 5.31% in 2022, then jumped 155.63% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $129000.0 in 2022, then advanced by 10.08% to $142000.0 in 2023, then jumped by 155.63% to $363000.0 in 2024, then advanced by 7.99% to $392000.0 in 2025, then decreased by 1.53% to $386000.0 in 2026.
- Business Quant data shows MDGL's Depreciation & Amortization (CF) at $386000.0 in Q1 2026, $392000.0 in Q4 2025, and $358000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | 386,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 386,000.00 |
| Mar 31, 2026 | 386,000.00 |
| Dec 31, 2025 | 392,000.00 |
| Dec 31, 2025 | 392,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 377,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Dec 31, 2024 | 363,000.00 |
| Dec 31, 2024 | 363,000.00 |
| Sep 30, 2024 | 298,000.00 |
| Sep 30, 2024 | 298,000.00 |
| Jun 30, 2024 | 267,000.00 |
| Jun 30, 2024 | 267,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Dec 31, 2023 | 142,000.00 |